...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International braz j urol >Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis
【24h】

Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis

机译：患有SipuEucel-T（APC8015）的免疫疗法在转移性阉割 - 难治性前列腺癌（MCRPC）患者中：系统评价和荟萃分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective To perform a systematic review and meta-analysis of all randomized controlled trials comparing the efficacy of Sipuleucel-T versus placebo for asymptomatic or minimally symptomatic metastatic castration-refractory prostate cancer (mCRPC). Materials ans Methods Several databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The endpoints were overall survival (OS), time to progression (TTP) and side effects. We performed a meta-analysis (MA) of the published data. The results are expressed as Hazard Ratio (HR) or Risk Ratio (RR), with their corresponding 95% confidence intervals (CI 95%). Results The final analysis included 3 trials comprising 737 patients. The TTP was similar in patients who received Sipuleucel-T or placebo (fixed effect: HR = 0.89; CI 95% = 0.75 to 1.05; p = 0.16), with no heterogeneity detected on this analysis (Chi2 = 2.14, df = 2 (P = 0.34); I2 = 6%). The results showed a higher overall survival in patients treated with Sipuleucel-T (fixed effect: HR = 0.74; CI 95% = 0.61 to 0.89; p = 0.001; NNT = 3). We found no heterogeneity on this analysis either (Chi2 = 1.46, df = 2 (P = 0.48); I2 = 0%). The incidence of adverse events (grade > 3) was the same in both groups. Conclusion Sipuleucel-T prolongs overall survival in patients with asymptomatic or minimally symptomatic mCRPC.
机译：目的对所有随机对照试验进行系统评价和荟萃分析，比较SipuEucel-T与安慰剂对无症状或最小症状转移阉割 - 难治性前列腺癌（MCRPC）的疗效进行比较。材料ANS方法搜索了几个数据库，包括Medline，Embase，Lilacs和Central。端点是总生存（OS），进展时间（TTP）和副作用。我们执行了已发布数据的Meta分析（MA）。结果表达为危害比（HR）或风险比（RR），其相应的95％置信区间（CI 95％）。结果最终分析包括3例患者3例试验。 TTP在接受Sipueucel-T或安慰剂的患者中类似（固定效果：HR = 0.89; CI 95％= 0.75至1.05; p = 0.16），在该分析上没有检测到异质性（Chi2 = 2.14，df = 2（ p = 0.34）; I2 = 6％）。结果表明，患有Sipueucel-T治疗的患者的总生存率较高（固定效果：HR = 0.74; CI 95％= 0.61至0.89; p = 0.001; NNT = 3）。我们发现这种分析中没有异质性（Chi2 = 1.46，df = 2（p = 0.48）; i2 = 0％）。两组中不良事件（级别> 3）的发生率相同。结论西普卢克-T-T延长无症状或最小症状MCRPC患者的整体生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号